Altimmune, Inc. (ALT)
| Market Cap | 604.81M +6.1% |
| Revenue (ttm) | 36,000 +80.0% |
| Net Income | -91.08M |
| EPS | -0.91 |
| Shares Out | 194.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,520,265 |
| Open | 2.940 |
| Previous Close | 3.020 |
| Day's Range | 2.930 - 3.110 |
| 52-Week Range | 2.560 - 6.440 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 15.45 (+396.79%) |
| Earnings Date | Aug 11, 2026 |
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Financial Performance
In 2025, Altimmune's revenue was $41,000, an increase of 105.00% compared to the previous year's $20,000. Losses were -$88.09 million, -7.33% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ALT stock is "Buy." The 12-month stock price target is $15.45, which is an increase of 396.79% from the latest price.
News
Altimmune initiated with an Outperform at Leerink
Leerink analyst Thomas Smith initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target Altimunne is an attractive play in an increasingly validated market for MASH therapeut...
Altimmune initiated with an Outperform at Leerink
Leerink initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target
Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management emphasized strategic progress, financial strength, and differentiation of pemvidutide in the evolving MASH/NASH market. Phase III trials are set to begin enrollment in the second half of the year, with a readout expected in 2029. Expansion into AUD and ALD is underway, with key data readouts and updates anticipated next quarter.
Altimmune Transcript: Jefferies Global Healthcare Conference 2026
Phase III enrollment for pemvidutide in MASH is set for later this year, supported by strong EASL data and robust funding. The program leverages AI tools and flexible endpoints, aiming for differentiation in a growing market, with phase II AUD data expected soon.
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
Altimmune (ALT) announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated l...
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today annou...
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antif...
Altimmune price target lowered to $20 from $25 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Altimmune (ALT) to $20 from $25 and keeps a Buy rating on the shares. The price target cut reflects…
Altimmune Slides: Corporate presentation
Altimmune has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Altimmune price target lowered to $11 from $14 at Citizens
Citizens lowered the firm’s price target on Altimmune (ALT) to $11 from $14 and keeps an Outperform rating on the shares. Pemvidutide is a differentiated and compelling metabolic dysfunction-associate...
Altimmune Earnings Call Transcript: Q1 2026
Raised $225M in April, boosting cash to $535M and securing runway through 2029. Advancing pemvidutide with phase III MASH trial to start H2 2026, phase II AUD data due next quarter, and strong focus on tolerability and efficacy to differentiate in a competitive market.
Altimmune Earnings release: Q1 2026
Altimmune released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Altimmune Quarterly report: Q1 2026
Altimmune has published its Q1 2026 quarterly earnings report on May 13, 2026.
Altimmune reports Q1 EPS (18c), consensus (25c)
“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune (ALT),” said Jerry Durso, president and CEO of Altimmune. “As a result of…
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET G...
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today annou...
Altimmune management to meet with Piper Sandler
Meeting to be held in New York on April 28 hosted by Piper Sandler.
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital...
Altimmune upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Corinne Johnson upgraded Altimmune (ALT) to Neutral from Sell with a price target of $2.50, up from $1. The company’s financing this week brings its pro forma…
Altimmune 64.25M share Spot Secondary priced at $3.00
Leerink and Barclays acted as joint book running managers for the offering.
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune announces common stock offering, no amount given
Altimmune (ALT) announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its…
Altimmune Announces Proposed Underwritten Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...